Gland Pharma, a global injection-focused company, faced several constraints in the first quarter of 2022-23, such as supply chain disruptions, cost escalation and insulin line closures. This has impacted revenue, EBITDA and PAT, which declined by 26%, 38% and 34.6% respectively. Despite this, analysts remain confident about the company’s future growth for a number of reasons. First, the development of injection has been one of